Calidi Biotherapeutics, Inc.
Veridion Score
Composite trend over time
Why is CLDI moving today?
Calidi Biotherapeutics Inc is a biotechnology company pioneering the development of targeted therapies with the potential to deliver genetic medicines to distal sites of disease. The company's proprietary RedTail platform features an engineered enveloped oncolytic virus designed for systemic delivery and targeting of metastatic sites. Its technology is intended to shield the virus from immune clearance, allowing virotherapy to effectively reach tumor sites, induce tumor lysis, and deliver potent genetic medicine(s) to metastatic locations. Its product candidates include The RedTail for Metastatic Solid Tumors, CLD-101 for Recurrent HGG; CLD-201 for Solid Tumors, and CLD-101 (NeuroNova) for Newly Diagnosed High Grade Glioma.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Warehouse intelligence for CLDI.
CLDI insider activity
Calidi Biotherapeutics, Inc.
No multi-insider buying cluster in the last 90 days
Net buying: $454K across loaded Form 4 rows.
Loaded official disclosures do not show all three sources aligned on this ticker.
| Filing date | Trade date | Insider | Title | Type | Price | Qty | Owned | Value | Receipt |
|---|---|---|---|---|---|---|---|---|---|
| 2025-12-16 | 2025-12-12 | Camaisa Allan | Insider | sell | $1.46 | 850 | 76,952 | $1K | SEC Form 4 |
| 2025-08-25 | 2025-08-21 | Leftwich Scott | Insider | buy | $2.00 | 125,000 | 130,650 | $250K | SEC Form 4 |
| 2025-08-25 | 2025-08-21 | Jackson Andrew C. | Insider | buy | $2.00 | 2,500 | 2,500 | $5K | SEC Form 4 |
| 2025-08-25 | 2025-08-21 | Schoeneck James A | Insider | buy | $2.00 | 75,000 | 76,134 | $150K | SEC Form 4 |
| 2025-08-25 | 2025-08-21 | Poma Eric E | Insider | buy | $2.00 | 25,000 | 25,000 | $50K | SEC Form 4 |
CLDI contract awards, year to date.
Public federal awards linked to this ticker.
CLDI lobbying filings, year to date.
Registered lobbying filings matched to Calidi Biotherapeutics, Inc..